Abstract 219P
Background
Tyrosine kinase inhibitor (TKI) combined with immune checkpoint inhibitor(ICI)had demonstrated efficacy as first-line therapy for mRCC patients(pts)in clinical trials. However, data on real-world outcomes were limited. Our study aimed to evaluate the effectiveness of tislelizumab plus TKI in pts with mRCC.
Methods
Demographic and clinicopathological data of pts with mRCC between July 2019 and November 2022 were retrospectively collected from Sun Yat-sen University Cancer Center. All pts received first-line treatment with TKI monotherapy (TKI group, mainly sunitinib) or tislelizumab plus TKI therapy (combination group,mainly plus axitinib). TKI group who failed first-line therapy received tislelizumab plus TKI as second-line regimen. Combination group who failed first-line therapy received TKI or ICI plus TKI as second-line regimen. Outcomes including the objective response rate (ORR), progression-free survival (PFS), PFS2 (defined as time from initial treatment to progression after first subsequent therapy or any-cause death.) and overall survival (OS) were calculated.
Results
Totally 136 pts were analyzed, with a median age of 57 (17-81) years. 72.1% were male, 71.3% had clear cell RCC, 78.8% had an IMDC intermediate/poor-risk disease, 62.5% had metastatic number≥2, metastatic organs included lung (47.1%), bone (27.9%), liver (13.2%) and brain (5.1%). The median follow-up was 26.4 (23.1-29.6) months. The combination group (n=61) had a significantly longer PFS compared with the TKI group (n=75) (median PFS (95% CI): 17.4 (13.9-20.9) vs 6.2 (5.5-6.9) months, P<0.001). Similarly, the PFS2 was longer in the combination group (median PFS2 (95% CI): 23.5 (7.7-39.3) vs 14.7 (11.1-18.3) months, P=0.011). Besides, ORR was remarkably improved in the combination group (44.3% vs 18.7%, P=0.001). Median OS was not reached for combination group and 42.9 months for TKI group (p = 0.081).
Conclusions
Our data demonstrated effectiveness of tislelizumab plus TKI as first-line treatment for mRCC pts in real world.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract